Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lance Wright

Neurology Memphis, TN Medical Doctor

NPI 1699756346 CMS profile 303477

6325 Humphreys Blvd, Memphis, TN 38120

Open in the dashboard

General payments

$18,613

922 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Lance Wright of Memphis, TN is reported in the CMS Open Payments database as having received $18,613 across 922 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,719 255
2024 General $3,805 193
2023 General $2,131 105
2022 General $1,763 58
2021 General $749 49
2020 General $876 35
2019 General $3,569 227

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lance Wright
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Lance Wright were reported at $5,719. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Lance Wright Neurology median Middle half National median
2019 $3,569 $474 $118–$2,177 $163
2020 $876 $367 $82–$2,309 $114
2021 $749 $438 $104–$2,547 $132
2022 $1,763 $442 $103–$2,388 $149
2023 $2,131 $464 $119–$2,312 $160
2024 $3,805 $468 $119–$2,323 $164
2025 $5,719 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,888 261 payments
  2. Medtronic, Inc. $2,261 30 payments
  3. EMD Serono, Inc. $1,349 56 payments
  4. UCB, Inc. $967 39 payments
  5. Teva Pharmaceuticals USA, Inc. $899 55 payments
  6. Novartis Pharmaceuticals Corporation $753 38 payments
  7. SK Life Science, Inc. $731 20 payments
  8. Lilly USA, LLC $730 39 payments
  9. Biogen, Inc. $619 22 payments
  10. Lundbeck LLC $613 26 payments
  11. Other $6,802 336 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,697 900 payments
  2. Travel and Lodging $1,420 11 payments
  3. Education $452 9 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $43 2 payments
Products named General payments · program years 2019–2025
  1. SYNCHROMEDII $2,253 29 payments
  2. UBRELVY $1,143 141 payments
  3. BOTOX $952 44 payments
  4. QULIPTA $875 110 payments
  5. OCREVUS $474 28 payments
  6. KESIMPTA $465 19 payments
  7. Rystiggo $430 14 payments
  8. VALTOCO $402 19 payments
  9. AIMOVIG $394 18 payments
  10. NURTEC ODT $390 38 payments
  11. Other $10,434 515 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

3,928

Median for Neurology: 833

Drug cost

$1,442,740

Median for Neurology: $202,670

Branded share of claims

25.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hizentra Immun Glob G(Igg)/Pro/Iga 0-50 Brand 11 $307,434
Ingrezza Valbenazine Tosylate Brand 35 $287,115
Nuplazid Pimavanserin Tartrate Brand 28 $160,865
Tysabri Natalizumab Brand 13 $118,732
Betaseron Interferon Beta-1b Brand 11 $104,336
Aubagio Teriflunomide Brand 11 $101,078
Aimovig Autoinjector Erenumab-Aooe Brand 73 $53,676
Xcopri Cenobamate Brand 25 $42,968
Ubrelvy Ubrogepant Brand 33 $33,579
Nurtec Odt Rimegepant Sulfate Brand 16 $32,942

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$1,810,209

Of which drugs: $1,635,833

Medicare patients

854

Average age 72

Services billed

252,524

528 women, 326 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 33%
Ischemic heart disease 33%
Depression 31%
Osteoporosis 21%
Alzheimer's or dementia 21%
Chronic kidney disease 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg J1576 Office 12 6,620 $353,284
Injection, romosozumab-aqqg, 1 mg J3111 Office 37 21,210 $184,907
Injection, lecanemab-irmb, 1 mg J0174 Office 22 168,700 $176,764
Injection, onabotulinumtoxina, 1 unit J0585 Office 36 13,255 $65,702
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 34 5,063 $1,179
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 16 64 $42

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
$388 — 13,255
Rystiggo
$311 — —
Leqembi
$262 — 168,700
KESIMPTA
$246 — —
VYEPTI
$218 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

922 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record